NEWS CENTER
SCROLL
Oct 24, 2024
24/ 10
Rona Therapeutics Unveils Extrahepatic siRNA Delivery Data in CNS Utilizing Receptor-Mediated Endocytosis and Novel siRNA Design At 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Jul 26, 2024
26/ 07
Rona Therapeutics announced that the self-developed APOC3 siRNA drug， RN0361，received approval for a Phase I clinical trial application in Australia
Jul 19, 2024
19/ 07
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Jun 13, 2024
13/ 06
Rona Therapeutics and EnnovaBio Pharmaceuticals Published Late Breaker Poster of First-in-class Liver Targeted CIDEB siRNA for MASH in EASL Congress 2024
Dec 29, 2023
29/ 12
Rona Therapeutics's First Self-developed siRNA Product has been Approved for Conducting Clinical Trial in China
Nov 12, 2023
12/ 11
Rona Therapeutics Participated in the 2023 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and Published Novel ApoC3 siRNA Preclinical Results
EXPLORER MORE
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...